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Background: Restless Legs Syndrome is very common in hemodialysis patients however there are no comparative
studies assessing the effectiveness of a non-pharmacological treatment to a classical treatment on parameters
related to syndromes’ severity and quality of life.
Methods: In this randomized, partially double blind, placebo controlled trial, thirty two hemodialysis patients with
restless legs syndrome were randomly assigned into three groups: 1) the exercise training group (N = 16), 2) the
dopamine agonists group (ropinirole 0.25 mg/d) (N = 8) and 3) the placebo group (N = 8). The intervention
programs lasted 6 months. Restless Legs Syndrome severity was assessed using the international severity scale,
physical performance by a battery of tests, muscle size and composition by computed tomography, body
composition by Dual Energy X Ray Absorptiometry, while depression score, sleep quality, daily sleepiness and
quality of life were assessed through questionnaires.
Results: Exercise training and dopamine agonists were effective in reducing syndrome’s symptoms by 46% (P = 0.009)
and 54% (P = 0.001) respectively. Within group changes revealed that both approaches significantly improved quality
of life (P < 0.05), however, only the dopamine agonists significantly improved sleep quality (P = 0.009). Within group
changes showed a tendency for lean body mass improvements with dopamine agonists, this reached statistical
significance only with the exercise training (P = 0.014), which also reduced fat infiltration in muscles (P = 0.044) and
improved physical performance (P > 0.05) in various tests. Between group changes detect significant improvements
with both exercise and dopamine agonists in depression score (P = 0.003), while only the dopamine agonist treatment
was able to significantly improve sleep quality, compared to exercise and placebo (P = 0.016).
Conclusions: A 6-month exercise training regime was as effective as a 6-month low dosage dopamine agonist
treatment in reducing restless legs syndrome symptoms and improving depression score in uremic patients. Further
research is needed in order to show whether a combination treatment could be more beneficial for the amelioration
of RLS.
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Restless Legs Syndrome (RLS) is a highly prevalent
sensory-motor disorder in the hemodialysis (HD) popu-
lation [1]. Dopamine agonists (DA) is the choice medica-
tion and is effective in the reduction of RLS symptoms
in patients suffering from idiopathic RLS [2]. However,
limited data exist regarding the therapeutic effectiveness
of DA in HD patients with a secondary form of the syn-
drome [3,4], called uremic RLS.
Recently published data indicate that patients with
uremic RLS are subjects of increased muscle atrophy
compared to RLS free counterparts [5]. Muscle atrophy
and the total lean body mass receives special concern
from the nephrologists as it has been related to high
mortality in the HD patients [6].
Even though, DA are the treatment of choice for the
amelioration of RLS symptoms, side effects and augmen-
tation phenomena have been commonly reported in the
literature [7]. Evidence from non-RLS individuals indi-
cated that dopaminergic agents may enhance physical
performance by delaying the onset of muscle-related
fatigue [8]. On the other hand, acute [9] or chronic [10]
exercise training has been used successfully in HD pa-
tients as a means of ameliorating RLS symptoms con-
comitantly improving aspects of quality of life (QoL).
It is known that both DA and exercise training can
ameliorate RLS symptoms however it has not yet
been elucidated whether treatment with DA could im-
prove parameters related to physical performance and
muscle size in patients with uremic RLS. The primary
aim of the current study was to compare the changes
across groups in the amelioration of RLS symptoms
in HD patients with RLS. The secondary aim was to
assess the changes across groups in aspects related to
QoL and overall life prognosis such as muscle size,
body composition and physical performance.
Methods
Ethics statement
The study was approved by the Human Research and
Ethics Committee of the University of Thessaly, and
by the bioethics committee of the University General
Hospital of Larissa, Greece. All patients gave their written
informed consent prior to study participation.
Study population
All patients were recruited from the hemodialysis unit of
the University Hospital of Larissa (UHL), Greece. The
study was performed from September 2007 to October
2009. All study measurements were performed at the
University Hospital of Larissa, Greece. RLS was diag-
nosed by a single RLS specialist-neurologist using the
standard criteria of the International RLS Study Group
(IRLSSG) [11]. Furthermore, the patients were includedin the study if they had at least one RLS episode per
week excluding the episodes that took place during the
dialysis session. RLS severity was assessed using the
IRLSSG severity rating scale [12].
The inclusion criteria for the study were: dialysis for at
least three months or more with adequate dialysis deliv-
ery and with stable clinical condition. In addition, all pa-
tients should have RLS and none of them should have
been treated with any medication for RLS prior to the
study.
Exclusion criteria included diagnosed neuropathies
(n = 3, clinically examined by a neurologist) or reasons
for being in a catabolic state (n = 2, opportunistic infec-
tions and active inflammation), within 3 months prior to
the start of the study, or with C-reactive protein blood
levels above 3.0 mg/l (n = 1), unable to exercise (n = 3) or
refuse to participate for personal reasons (n = 4). None of
the recruited patients were engaged in any systematic ex-
ercise training programme. A specialized in RLS neurolo-
gist examined the patients in order to assess any potential
augmentation phenomena during the study period, using
standard criteria [11].
Over all, thirteen patients fulfill the exclusion criteria
(Figure 1) while thirty-two stable HD patients were en-
rolled to the study.
Patients were randomly assigned, in a 2-1-1 fashion, in
three groups. The first group received 6 months of
intradialytic exercise training (N = 16 – Exercise group),
the second group received the classical RLS treatment
with DA (ie Ropinirole) (N = 8 – Dopamine agonist
group) while the third group received matching placebo
pills (N = 8 – Placebo group). All three interventions
lasted for six months in order to maximize the exer-
cise effect and to minimize the well-known placebo
effect seen in RLS patients. Both the patients and the
investigators were blinded to the type of the medica-
tion used in the second and third group (double-blind
design).
Medication
The DA used was ropinirole (Adartrel®, GlaxoSmithKline,
UK). It was powdered and inserted in an empty capsule
(the rest was filled with plain flour), in a 0.25 mg/dose,
which was maintained stable until the end of the
study. We consciously decided not to perform a dose
titration in order to minimize any augmentation phe-
nomena that could affect the study outcomes. Placebo
was made by plain flour filled in the same type of capsules.
Patients were instructed to receive their capsules once
daily, 2 hours before bedtime. Both the ropinirole and
the placebo capsules were made at the UHL pharmacy
and their packaging was identical. The efficacy of DA or
placebo on RLS symptoms severity was evaluated by the
IRLSSG scale [12].
Figure 1 Patient recruitment flow diagram. Disposition of the patients into the three groups as follows: aerobic exercise training group,
dopamine agonists group and placebo group.
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The exercise training took place 3-times per week during
the HD session, for six months and consisted of cycling
in a recumbent cycle ergometer (Model 881 Monark
Rehab Trainer, Varberg, Sweden) at an intensity of 60-65%
of the patient’s maximal exercise capacity (in Watts),
which was estimated through during a previous HD
session [13]. The exercise intensity was readjusted on
a monthly base.
Hemodialysis procedure
The patients underwent the HD therapy (Fresenius
4008B, Oberursel, Germany) 3 times/week with low flux,
hollow-fiber dialysers and bicarbonate buffer. The HD
session lasting approximately 4 hours. An enoxaparin
dose of 40–60 mg was administered intravenously before
the beginning of each HD session. EPO therapy was
given after the completion of HD session in order to
normalize hemoglobin levels within 11–12 (g/dL).
Physical performance
The patient’s physical performance levels were assessed via
a battery of specific tests, including the North Staffordshire
Royal Infirmary (NSRI) walk test [14], two Sit-to-Stand
tests (STS-5 STS-30 and STS-60) and two gait speed tests
(normal and fast walk) [15].Body and muscle composition
The patient’s whole body and regional fat and lean body
mass were measured by a dual energy x-ray absorptiom-
eter (DEXA) system (Lunar model DPX Madison, WI),
as previously described [16].
Muscle size and composition were assessed by analyz-
ing images collected by a Computed Tomography (CT)
system (Philips, Tomoscan SR5000) [17,18]. Muscle cross
sectional area (CSA), subcutaneous adipose tissue (SAT)
and extramyocellular lipids (EMCL) accumulation were
assessed by images collected using the same CT system by
collecting six images of 2 cm apart at the larger girth of
the right thigh for each patient. Image analysis of the CT
slices was performed using a customized software pro-
gram written in IDL (Interactive Data Language Research
Systems, Inc., Boulder, CO). This software, based on varia-
tions in signal intensity, allowed for the quantification of
fat, muscle and miscellaneous components (connective
tissue, fascia, intramuscular fat) expressing the data as
area (cm2) and percentage of tissue composition (fat%,
muscle% and miscellaneous%).
Questionnaires
All questionnaires were completed with the interview
method, by experienced personnel. The patient’s subject-
ive quality of life outcomes were evaluated by using a
Table 1 Patient’s characteristics data divided in three







N 15 7 7
Female/Male 4/11 3/4 2/5
Age (yr) 56.4±12.5 55.7±10.4 56.8 ±16.5
BMI (Kg/m2) 27.0±3.6 27.4±5.6 25.3±1.7




Iron (μg/dl) 58.6± 17.4 64.5±14.2 61.4±12.6
Hct 36.8±5.7 40.0±3.6 37.1±2.0
Hb (g/dL) 12.1±2.0 13.5±1.1 12.0±0.6
All data are mean ± SD. Abbreviations: BMI Body mass index, Kt/V Dialysis
efficiency, Hct Hematocrit, Hb Hemoglobin.
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36 can range from 0 to 100, while higher scores indicate
better health status. The 8 multi-item scales of the SF-36
were summarized into two components (mental and
physical component respectively) [19].
The patients’ depression levels were assessed by using
the self-rating depression scale developed by Zung [20].
The cut-off point for the diagnosis of clinical depression
in the Zung scale is above 50.
The Epworth sleepiness scale was used to assess the
daily sleepiness level of the patients [21]. Briefly, this
scale consists of questions referring to eight situations.
The patients are asked to rate on a scale of 0 up to 3 how
likely they would be to doze off or fall asleep during the 8
situations. Outcome scores can range from 0 to 24. A
score above 10 is considered to be pathological sleepiness.
Finally, a weekly sleep diary was used to evaluate
the patient’s quality of sleep. The diary was adapted
from the University of Massachusetts Medical School
website (http://healthnet.umassmed.edu/mhealth/Weekly
SleepQuestionnaire.pdf). Briefly, the sleep diary contained
questions regarding how often during the previous
week HD patients experienced any of the following:
(1) difficulties falling asleep, (2) number of nocturnal
awakenings, (3) difficulties remaining asleep, (4) the
sensation of waking-up tired and fatigued, (5) day
time stress and (6) how often did they feel refreshed
after the night’s sleep. The sleep diary was scored as fol-
lows: ‘never’ (0 points), ‘1–2 times a week’ (1 point), ‘3–5
times a week’ (2 points), ‘6–7 times a week’ (3 points). For
question number 6 the scoring was reversed with 3 points
for the answer ‘never’, and 0 points for the answer ‘6–7
times a week’. The sleep diary score was calculated as the
sum of the total points with the minimum at zero points
and the maximum score at 18.
Biochemical assessment
The biochemical examination of blood samples was
performed at the clinical lab of the UHL under standard
hospital procedures. A single-pool Kt/V was calculated
from using the Daugirdas II equation [22].
Statistical analysis
The baseline characteristics of the three groups were
compared using one-way ANOVA. The changes within
the three groups from baseline to the end of the 6-
month intervention period were evaluated using paired
t-tests while chi-square was used for categorical vari-
ables. The absolute changes between the three groups
from baseline to the end of the 6-months intervention
were evaluated via one-way ANOVA. Finally, Spearman
rank correlation test was used to assess the relation
between the examined variables. All statistical analyses
were performed using the SPSS version 15.0 (SPSS Inc.Chicago, Illinois). Data in the text are presented as
mean ± SD and the level for statistical significance
was set at P ≤ 0.05.
Sample size calculations were conducted based in IRLS
score values after pharmacological [IRLS 26(5) vs 11(9)]
and exercise treatment [IRLS 26(6) vs 15(9)] from previ-
ous published work [10,23]. Even though the dose of the
pharmacological treatment used for the power calcula-
tion [23] was higher compared to our study, the magni-
tude of change was almost identical (42% vs 45%). The
resulting minimum required sample size was an average
of 6 for the pharmacological approach and an average of
9 for the exercise approach for 2-sided type 1 and type 2
errors of 5%.
Results
The study’s flow chart is presented in Figure 1. Briefly a
total of forty-five patients were screened while thirty-
two patients enrolled in the study and were randomly
assigned in one of the three groups. Three patients
dropped out for reasons unrelated to the study during
the follow-up period making those who completed the
study twenty nine.
The patient’s characteristics are presented in Table 1.
No significant differences were observed in the patient’s
baseline characteristics and none of these values changed
after the 6-month intervention in all three groups (post
data not shown) (P > 0.05).
The baseline score in the IRLS severity scale, Zung de-
pression scale, sleep diary, daily sleepiness status and
overall QoL score did not differ between the three
groups. Both exercise and DA intervention were equally
effective in reducing RLS symptoms (P = 0.012) and de-
pression score (P = 0.003) compared to the placebo arm
while the DA group was more effective in improving
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groups (ANOVA – between groups effect) (Table 2).
DA and exercise training positively affected the SF-36-
PCS score (P = 0.000 and P = 0.003), DA positively af-
fected SF-36-MCS (P = 0.004), however, even though
the improvements rich the 18%, 41% and 9% for the PCS
and 15%, 61% and 4.5% (worsening) in the MCS in the
Exercise, DA and Placebo groups, the Δ-changes values
did not reach statistical significant levels (P < 0.05).
In addition, depression score appeared to be signifi-
cantly improved (P = 0.002) in the exercise group afterTable 2 Quality of life, depression, daytime sleepiness, sleep































95% CI of Δ change 21.7 to 1.2
All data are mean ± SD. Abbreviations: IRLS International restless legs syndrome sev
component summary, PCS Physical component summary.
#Significantly different than placebo group.
¶Significantly different than exercise group.
†Significantly different from the respective baseline value.the 6 months, whereas in contrast, in the placebo group, a
significant worsening of the score was detected (P < 0.05).
IRLS score was significantly reduced after the inter-
vention with exercise or DA by 46% (P = 0.009) and 54%
(P = 0.001) respectively, whereas no significant changes
were found in the placebo group after the 6 months
period (P = 0.732) (paired t-test).
The physical performance data are presented in Table 3.
For the baseline, no significant differences were found
between the three groups in all physical performance
tests performed (P > 0.05). Exercise training significantlyquality and RLS symptom’s severity data divided in three
ervention












−16.96 to 2.12 11.70 to −0.07
24.14±5.55 19.71±7.49
11.57±7.84† 18.57±10.65
- 12.57±5.31# - 1.14±8.43








25.7 to 14.5 20.2 to −7.9
erity scale, SF-36 Self reported quality of life questionnaire, MCS Mental
Table 3 Physical performance data divided in three groups according to the assigned intervention
Variables Exercise group Dopamine agonists group Placebo group
STS- 5 (sec)
Baseline 10.12±2.56 8.89±0.74 9.69±0.46
6-m post 8.24±2.34† 8.48±1.72 8.81±0.66
Δ Change −1.75±2.32 - 0.41±1.63 - 0.88±0.76
95% CI of Δ change −3.03 to −0.47 −1.91 to 1.09 −1.58 to −0.18
STS-30 (rep)
Baseline 14.73±4.00 14.83±2.13 14.75±0.9
6-m post 17.84± 4.68† 14.50±2.58 17.25±3.2
Δ Change 2.96±4.87 - 0.33±2.33 2.50±2.51
95% CI of Δ change 5.65 to 0.27 −0.63 to −0.03 4.81 to −0.19
STS-60 (rep)
Baseline 27.95±8.38 26.60±3.64 30.0±3.16
6-m post 32.50±9.34 27.40±7.40 32.0±5.35
Δ Change 4.26±8.23 0.80±4.65 2.00±3.26
95% CI of Δ change 8.77 to −0.25 5.09 to −3.49 5.0 to −1.0
Normal Walk (sec)
Baseline 6.09±1.24 5.69±1.53 5.30±1.06
6-m post 5.81±1.49 6.14±1.63 5.38±1.09
Δ Change −0.42±1.36 0.44±1.46 0.07±0.27
95% CI of Δ change −1.17 to 0.33 1.78 to −0.90 0.31 to −0.17
Fast Walk (sec)
Baseline 3.86±0.66 3.57±0.40 3.77±0.47
6-m post 3.65±0.75 3.56±0.40 3.57±0.41
Δ Change −0.28±0.65 - 0.01±0.19 - 0.19±0.40
95% CI of Δ change −0.63 to 0.07 −0.18 to 0.16 −0.55 to 0.17
NSRI test (sec)
Baseline 84.46±21.35 70.10±20.46 52.48±14.24
6-m post 75.02±26.60† 67.68±20.78 53.44±17.13
Δ Change −9.25±13.41 −2.41±6.52 0.96±4.01
95% CI of Δ change −16.6 to −1.85 −8.41 to 3.59 4.65 to −2.73
All data are mean ± SD. Abbreviations: STS-5 Sit-to- stand test 5-repetitions, STS-60 Sit-to- stand test 60 seconds, STS-30 Repetitions’ measurement at 30 seconds
as part of the STS-60 test, NSRI North staffordshire royal infirmary test.
†Significantly different from the respective baseline value.
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0.023), STS-5 (P = 0.014) and STS-30 (P = 0.040) tests (P <
0.05), whereas no significant changes were observed in
the DA and in the placebo groups (P > 0.05).
DEXA and CT data are presented in Table 4 and Table 5
respectively. Total lean body mass (LBM) appeared to
be significantly increased after the exercise training
(P = 0.014), however the Δ change value was not sig-
nificantly different between the groups. The EMCL
were significantly reduced after the exercise interven-
tion (P = 0.044).
The post exercise IRLS severity score was negatively
correlated with the post exercise QoL score (r = − 0.719,P = 0.045) and the amount of fat infiltration in the
muscles (EMCL, r = − 0.829, P = 0.021) post training.
Finally, none of the patients reported any drug ad-
verse reactions or augmentation phenomena from the
three interventions.
Discussion
Both low dose ropinirole and aerobic exercise training
treatment were found to equally ameliorate RLS symp-
toms and improve depression score, while no side effects
were reported in either treatment. However, only dopa-
mine agonists improve subjective sleep quality while the
placebo group reported a significant deterioration in the
Table 4 Body composition data divided in three groups according to the assigned intervention
Variables Exercise group Dopamine agonists group Placebo group
DEXA-derived data
Total Body Fat (%)
Baseline 30.9±9.0 31.9±11.2 26.0±5.4
6-m post 30.5±8.1 27.1±7.5 28.5±5.8
Δ Change - 0.38±1.83 - 4.71±10.86 2.45±2.24
95% CI of Δ change −1.39 to 0.63 −14.70 to 5.32 4.50 to 0.38
% Legs Fat
Baseline 32.7±10.2 29.9±13.2 26.2±4.9
6-m post 32.3±9.3 25.1±8.9 28.5±5.2
Δ Change - 0.37±2.71 - 4.86±11.03 2.27±6.50
95% CI of Δ change −1.86 to 1.12 −15.05 to 5.28 8.27 to −3.73
Total LBM (Kg)
Baseline 45.3±7.8 47.7±5.4 46.1±5.0
6-m post 46.7±8.3† 49.8±3.4 45.4±5.1
Δ Change 1.38±1.23 2.12±4.85 - 0.66±0.71
95% CI of Δ change 2.06 to 0.70 6.61 to −2.37 −1.31 to −0.01
All data are mean ± SD. Abbreviations: LBM Lean body mass.
†Significantly different from the respective baseline value.
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the treatment.
The DA ropinirole is considered an effective approach
for the amelioration of RLS symptoms in both idiopathic
[2] and uremic [4] RLS patients, and is the treatment
of choice despite some reports of augmentation prob-
lems when dosage increases [7]. Still, there is recent
evidence that aerobic exercise training could effect-
ively reduce RLS symptoms, in both categories of RLS
patients [9,24].
Our study, comparing these two approaches, showed
that both aerobic exercise training and the starting dose
of ropinirole treatment could equally ameliorate the se-
verity of RLS symptoms (by 46% and 54% respectively)
compared to placebo.
To the best of our knowledge, this is the first study to
compare the classical RLS pharmacological treatment
over an alternative but very promising approach such as
exercise training. The ropinirole dosage used in our trial
was the minimum approved in order to effectively re-
duce the RLS symptoms and at the same time avoid aug-
mentation phenomena [2]. The low dosage employed
could explain the lack of substantial difference in the re-
duction of IRLS score between the classical treatment
and the exercise training. It should be noted that im-
provements in other studies were reported to reach 75%
in the IRLS severity scale, using however dosages that
ranged from 0.75 mg/day (already higher dosage than
ours) up to 2 mg per day [4]. The uniqueness of the
current study is that by using the lower ropiniroledosage we were able to avoid any augmentation symp-
toms and confer clinical benefit that was comparable to
the improvement achieved by a non-pharmacological
life-style modification approach, such as exercise.
While further work is needed based on our results, it
seems that HD-RLS patients, at least the ones without
advanced symptomatology, could employ an alterna-
tive and healthier control of their RLS symptoms if
they adopt exercise.
According to the literature, a substantial placebo effect
is a common outcome in most of the placebo-controlled
RLS studies [25]. Interestingly, in our study, the patients
who received placebo in the intervention period, exhibit
improvements in the RLS severity only by 6%. It is
noteworthy that this is the first trial that provide data
regarding placebo-effect in uremic RLS patients. We
hypothesize that the low placebo-effect that observed
in our study may lie to the length of the treatment
(6-months) as well as to the small sample size of the
placebo group. We believe that in uremic patients,
the maintenance of placebo-effect is limited when the
intervention last for a long period of time such as the
6 months. Furthermore, a closer look on the individual’s
placebo group data reveals that 3 patients experienced a
slight worsening instead of relief in the RLS symptoms,
fact that significantly reduce the potential placebo-effect
of the current study.
The exercise-induced reduction in RLS symptoms
could not be fully explained by the current data. Aerobic
exercise training, apart from the recognized long term
Table 5 Muscle composition and size data divided in three groups according to the assigned intervention
Variables Exercise group Dopamine agonists group Placebo group
EMCL CSA (cm2)
Baseline 13.9±5.1 7.6±2.1 10.0±5.2
6-m post 11.2±5.8 6.8±3.6 9.4±2.0
Δ Change −2.62±5.15 −0.79±3.33 −0.61±3.92
95% CI of Δ Change −5.46 to 0.22 −3.86 to 2.21 −4.23 to 3.01
EMCL (%)
Baseline 10.9±3.8 8.7±3.6 8.7±3.9
6-m post 8.2±3.5† 7.1±2.7 8.4±1.5
Δ Change −2.70±3.90 −1.65±3.45 −0.21±3.54
95% CI of Δ Change −4.85 to −0.55 −4.83 to 1.53 −3.48 to 3.06
Muscle CSA (cm2)
Baseline 99.5±14.5 82.5±22.5 98.9±7.3
6-m post 106.8±24.4 89.4±24.5 95.8±2.0
Δ Change 7.32±16.03 6.93±17.66 - 3.15±7.87
95% CI of Δ Change 16.18 to −1.54 23.22 to −9.39 −10.42 to 4.12
Muscle (%)
Baseline 87.9±3.7 85.7±7.2 88.1±3.9
6-m post 88.9±4.5 88.1±5.9 88.2 ±2.2
Δ Change 0.96±5.50 2.39±4.89 0.07±1.64
95% CI of Δ Change 4.00 to −2.04 8.90 to −2.12 1.58 to −1.44
SAT CSA (cm2)
Baseline 142.8±57.8 88.7±46.7 103.6±28.4
6-m post 143.8±64.8 95.5±39.3 99.7±14.9
Δ Change 0.98±18.88 6.80±19.34 −3.95±17.97
95% CI of Δ Change 11.42 to −9.46 24.67 to −11.07 −20.55 to 12.65
All data are mean ± SD. Abbreviations: EMCL Extramyocellular lipids (fat infiltration), CSA Cross sectional area, SAT Subcutaneous adipose tissue.
†Significantly different from the respective baseline value.
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also acute benefits on the human brain by increasing the
levels of an endogenous opioid called β-endorphin [26].
In a study of Esteves and colleagues in non-uremic
patients, an inverse relationship was observed be-
tween β-endorphin release after exercise training and
periodic limb movements index [27]. It is also known
that the opioid system in the brain is involved in the
pathophysiology of RLS [28] while treatments in the
past using opioids successfully reduced the severity of
the syndrome [29]. Interestingly, in a recent study, β-
endorphins levels were found to be reduced in the
thalamus of patients with idiopathic RLS [30]. That find-
ing supports the possible mechanism for explaining the
exercise benefit observed in our study, demanding fur-
ther examination in the future.
Aerobic exercise training improved on patient’s phys-
ical performance, confirming previous data in HD patients
with [10] or without [31] RLS, however the observed
changes were statistical significant only on the withingroup comparisons and not compared to placebo group.
The fact that exercise training improved parameters
of the SF36 QoL questionnaire, LBM and muscle mass
could explain the improved physical performance. Im-
proving physical performance in a frail population, such
as the HD patients, bears high clinical significance as the
inactivity and the sedentary lifestyle are associated with
poor QoL, comorbidities and increased mortality [31].
Previous studies have shown that dopaminergic agents
can improve physical performance by reducing general
fatigue in patients with Parkinson’s disease [8]. In our
study, ropinirole administration did not show a meas-
urable ergogenic effect on patients’ performance. This
could be explained partially by the low ropinirole dos-
age used, in addition that, this study did not employ
an “all out” exercise performance test that could re-
veal an underlying ergogenic effect (as stressing such
patients to their limits is not advisable).
It is well known that the HD patients are characterized
by a progressive decline in total lean body and muscle
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effect of the dialysis treatment [33]. Interestingly, recent
data reveal that the HD patients with RLS may exhibit in-
creased muscle atrophy compared to their free-RLS coun-
terparts [5]. Aerobic [34] or resistance exercise training
[35] could reverse or halt muscle wasting in HD patients,
improving QoL and survival. Even though that LBM and
muscle mass appeared to be improved in the exercise
group after the intervention period (within groups com-
parison); no significant changes were detected compared
to the placebo or ropinirole group. The low sample size
seems to be the most logical explanation for the above
findings.
According to the literature, DA could improve muscle
mass through reduction in muscle fatigue [8], and by in-
creasing growth hormone release and enhancing prolac-
tin inhibition [36] and therefore promoting muscle
anabolism. Both the exercise training and DA treatment
could positively influence the level of LBM, however,
the observed changes did not reach statistical signifi-
cance levels compared to placebo arm. Improving LBM is
something that should receive special attention from
health care providers and the nephrologists since malnu-
trition and wasting are seen very often in the dialysis unit
and are known to predict survival in this patient popula-
tion [6].
Intramuscular lipid content is independently associ-
ated with diabetes mellitus in HD patients [37]. A seden-
tary life style lead to low physical fitness, which in turn
has been linked to insulin resistance engrossing patients
into a vicious circle of inactivity and muscle loss [38,39].
In our study, the CT analysis of the exercise group re-
vealed evidence of improved muscle atrophy with con-
comitant reduction in the intramuscular fat deposits
(extramyocellular lipids-EMCL) after the 6 months inter-
vention (within group differences) (Table 5). However,
the small sample size did not allow us to make safe con-
clusions regarding the superiority of exercise training
compare to placebo in terms of reducing EMCL, as no
significant differences were found between groups. The
effect of exercise training in the reduction of fat infiltra-
tion in the skeletal muscles could be considered as an
additional benefit towards the improvement of insulin
resistance, and possibly lowering the risk for the early
development of diabetes mellitus. The latter bears high
clinical significance as the HD patients consist of a
population with low-physical fitness levels [31] and with
increased risk of developing insulin resistance and dia-
betes mellitus [40], especially those who have disturbed
sleep [41].
Low QoL is associated with high mortality and high
hospitalization rate as well as low adherence to medica-
tion in patients with chronic diseases [42]. Treatment
with either ropinirole [43] or exercise training [10] inuremic RLS patients has been reported to improve QoL.
According to the within group differences, both the DA
and exercise groups earned a significant increase in the
PCS of the SF36, while only DA group resulted to sig-
nificant improvements in MCS of the SF36.
It is evident now that uremic RLS impairs significantly
sleep quality and quantity [44]. In the current study, DA
treatment significantly improved subjective sleep quality,
confirming previous data in uremic RLS patients [4].
Both the DA and exercise training treatments did not
improve daily sleepiness levels, confirming previous data
[2,10] however, the majority of the patients had scored
below the cutoff point (>10.0) that declare severe daily
sleepiness.
The HD patients often suffer from depression symp-
toms [45] while higher scores in depression are observed
in those with uremic RLS [46]. On the other hand, exer-
cise training appears to have a rejuvenating effect de-
creasing depression levels in HD patients [31]. In our
study, both the DA and the exercise training group
reported significant improvements in depression score,
whereas in contrast, depression levels appeared signifi-
cantly worse in the placebo group after the 6-month
period, clearly showing the negative effect that RLS can
have if left untreated.
Even though the uniqueness of our study as well as
the laborious methodology and highly skilled personnel
required, a number of limitations remain. Due to the na-
ture of the exercise intervention, a complete blinding in
the exercise group was not possible. This could have in-
duced a source of bias towards exercise intervention. In
the current study we were not able to perform an over-
night polysomnographic study in order to objectively
evaluate sleep quality and quantity as well as to assess
the periodic legs movements in sleep. In addition, no
beta endorphins levels were assessed after training in
order to further support our hypothesis. Even though
the sample of our study was homogenous and recruited
from the same dialysis unit, there were some numerical
(not statistical) differences in some of the baseline char-
acteristics between the three groups. In our study, the
dosage of the ropinirole treatment was the minimum ac-
cepted in order to avoid any augmentation phenomena,
however by not performing a dosage titrating we elimi-
nated the comparability of our data to the studies using
higher doses. Finally, residual renal function evaluation,
a factor that may contribute to symptoms onset, was not
included in the present study.
In conclusion, this is the first study comparing exercise
training with dopamine agonists’ treatment in the ameli-
oration of RLS symptoms, in patients with uremic RLS.
Given the low and safe dosage of DA, we verified that
both approaches were able to reduce RLS severity score
with no side effects in either treatment group, in uremic
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ment of RLS symptoms with placebo led to worsening
depression symptoms. Exercise training and low dosage
of dopamine agonists are equally effective treatments in
the amelioration of RLS symptoms in HD patients with
uremic RLS. While further work is needed based on our
results, it seems that HD-RLS patients, at least the ones
without advanced symptomatology, could employ an al-
ternative and healthier control of their RLS symptoms if
they adopt exercise.
Conclusion
A 6-month exercise training regime was as effective
as a 6-month low dosage dopamine agonist treatment
in reducing restless legs syndrome symptoms and im-
proving depression score in uremic patients. Further
research is needed in order to show whether a combin-
ation treatment could be more beneficial for the amelior-
ation of RLS.
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